147 related articles for article (PubMed ID: 37471110)
1. Targeting STAT5B in T-cell acute lymphoblastic leukemia.
Veloso A; Cools J
Blood; 2023 Jul; 142(3):215-217. PubMed ID: 37471110
[No Abstract] [Full Text] [Related]
2. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
3. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.
Kontro M; Kuusanmäki H; Eldfors S; Burmeister T; Andersson EI; Bruserud O; Brümmendorf TH; Edgren H; Gjertsen BT; Itälä-Remes M; Lagström S; Lohi O; Lundán T; Martí JM; Majumder MM; Parsons A; Pemovska T; Rajala H; Vettenranta K; Kallioniemi O; Mustjoki S; Porkka K; Heckman CA
Leukemia; 2014 Aug; 28(8):1738-42. PubMed ID: 24573384
[No Abstract] [Full Text] [Related]
4. A new hope for early T cell precursor acute lymphoblastic leukemia therapy based on STAT5+ leukemic stem cell targeting.
Pelayo R
J Leukoc Biol; 2023 Oct; 114(5):381-383. PubMed ID: 37607260
[TBL] [Abstract][Full Text] [Related]
5. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
Bandapalli OR; Schuessele S; Kunz JB; Rausch T; Stütz AM; Tal N; Geron I; Gershman N; Izraeli S; Eilers J; Vaezipour N; Kirschner-Schwabe R; Hof J; von Stackelberg A; Schrappe M; Stanulla M; Zimmermann M; Koehler R; Avigad S; Handgretinger R; Frismantas V; Bourquin JP; Bornhauser B; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2014 Oct; 99(10):e188-92. PubMed ID: 24972766
[No Abstract] [Full Text] [Related]
6. Rare occurrence of a STAT5B N642H mutation in adult T-cell acute lymphoblastic leukemia.
Ma X; Wen L; Wu L; Wang Q; Yao H; Wang Q; Ma L; Chen S
Cancer Genet; 2015; 208(1-2):52-3. PubMed ID: 25749351
[No Abstract] [Full Text] [Related]
7. A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling.
Bessette K; Lang ML; Fava RA; Grundy M; Heinen J; Horne L; Spolski R; Al-Shami A; Morse HC; Leonard WJ; Kelly JA
Blood; 2008 Jan; 111(1):344-50. PubMed ID: 17890450
[TBL] [Abstract][Full Text] [Related]
8. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
9. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
11. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
12. Emerging Necessity of Myeloid Mutational Analysis in Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL).
Tariq H; Shetty S
Turk J Haematol; 2023 Aug; 40(3):227-229. PubMed ID: 37431282
[No Abstract] [Full Text] [Related]
13. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T; Sorger H; Manhart G; Ruge F; Prutsch N; Zimmerman MW; Eder T; Abdallah DI; Maurer B; Wagner C; Schönefeldt S; Spirk K; Pichler A; Pemovska T; Schweicker C; Pölöske D; Hubanic E; Jungherz D; Müller TA; Aung MMK; Orlova A; Pham HTT; Zimmel K; Krausgruber T; Bock C; Müller M; Dahlhoff M; Boersma A; Rülicke T; Fleck R; de Araujo ED; Gunning PT; Aittokallio T; Mustjoki S; Sanda T; Hartmann S; Grebien F; Hoermann G; Haferlach T; Staber PB; Neubauer HA; Look AT; Herling M; Moriggl R
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618957
[TBL] [Abstract][Full Text] [Related]
14. Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes.
Chen B; Yi B; Mao R; Liu H; Wang J; Sharma A; Peiper S; Leonard WJ; She JX
PLoS One; 2013; 8(2):e56600. PubMed ID: 23457589
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
[No Abstract] [Full Text] [Related]
16. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
17. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
18. A Novel Case of Concurrent T-cell and Early T-cell Precursor Lymphoblastic Lymphoma in an Adolescent Female.
Treinen C; Abu-Arja MH; Kahwash SB; Rangarajan HG; Willen F; Audino AN
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e550-e553. PubMed ID: 34310470
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
Onishi Y; Furukawa E; Kamata M; Fukatsu M; Kameoka Y; Hatta S; Hamada H; Oyake T; Kai T; Sukegawa M; Nakajima S; Yanagiya R; Yamaguchi K; Takahashi T; Harazaki Y; Izumi T; Murai K; Ito S; Ikezoe T; Ishizawa K; Takahashi N; Harigae H
Int J Hematol; 2023 May; 117(5):738-747. PubMed ID: 36757523
[TBL] [Abstract][Full Text] [Related]
20. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia.
Genescà E; Morgades M; Montesinos P; Barba P; Gil C; Guàrdia R; Moreno MJ; Martínez-Carballeira D; García-Cadenas I; Vives S; Ribera J; González-Campos J; González-Gil C; Zamora L; Ramírez JL; Díaz-Beya M; Mercadal S; Artola MT; Cladera A; Tormo M; Bermúdez A; Vall-Llovera F; Martínez P; Amigo ML; Monsalvo S; Novo A; Cervera M; García-Guiñon A; Juncà J; Ciudad J; Orfao A; Ribera JM
Haematologica; 2020 Jun; 105(6):e294-e297. PubMed ID: 31537688
[No Abstract] [Full Text] [Related]
[Next] [New Search]
